What Is Apitegromab?

1. How does apitegromab work?

Myostatin, also called GDF8, belongs to the TGF-β family of growth factors and acts as a brake on skeletal muscle growth. The body makes it as an inactive precursor wrapped in a “prodomain.” Two enzyme cuts are needed before the active hormone is released (Pirruccello-Straub and colleagues, 2018).

Most drugs aimed at this pathway block the active hormone or its receptor. Apitegromab works one step earlier. A crystal structure published by Dagbay and colleagues shows the antibody gripping the “arm” region of the prodomain, which differs from the same region in related growth factors. That grip keeps the complex latent and shields the sites the enzymes need to cut.

The developers report that it does not bind mature myostatin or closely related growth factors (Welsh and colleagues, 2021). The goal of that selectivity is to avoid side effects seen with broader blockers of the activin pathway.

What the animal work showed

In mice, a mouse version of the antibody increased muscle mass, function and bone measures in an SMA model that was also given an SMN-restoring drug (Long and colleagues, 2019). These are animal results; human outcomes are covered below.

Two other compounds on glp1.app act on the same growth-factor system in different ways: follistatin-344, which relates to a natural myostatin-binding protein, and ACE-083. WADA places all of these approaches in the same prohibited class.

2. Is apitegromab FDA approved?

Yes, for one indication. The Isembyld label covers spinal muscular atrophy (SMA) in adults and children aged 2 and older who are currently on an SMN2-targeted drug. SMA is a genetic disease in which the motor neurons that drive muscles are lost. Nusinersen and risdiplam act on that nerve problem; apitegromab is meant to add a muscle-side treatment.

The road to approval ran through manufacturing, not efficacy:

When the EU application was withdrawn, the EMA’s provisional view was that the drug could not yet be authorized because compliance of the manufacturing site with EU good manufacturing practice had not been confirmed. The company now forecasts an opinion from the EMA’s medicines committee in the first half of 2027. That is a company expectation, not a regulatory decision.

Apitegromab is not approved for obesity, weight loss or muscle preservation in any country.

3. What did the SMA trials show?

The pivotal study, SAPPHIRE, was double-blind and placebo-controlled across 48 hospitals in Europe and the US. It enrolled 188 people aged 2–21 with type 2 or 3 SMA who could not walk, all already on nusinersen or risdiplam. The main measure was the Hammersmith Functional Motor Scale-Expanded (HFMSE), a 33-task motor score with a maximum of 66.

Children aged 2–12 (n = 156) were split evenly among 20 mg/kg, 10 mg/kg and placebo every 4 weeks for 12 months. Twelve-month results in that group:

The 10 mg/kg row comes from the FDA label. “Nominal” means that p-value sat outside the trial’s formal testing order. On the labeled dose, 34.2% of children gained at least 3 HFMSE points, compared with 13.5% on placebo.

Put plainly, untreated patients drifted slightly downward while treated patients gained a little. The double dose did no better, which is why the label recommends 10 mg/kg.

Earlier, uncontrolled data

The phase 2 TOPAZ trial gave apitegromab to 58 patients aged 2–21 with no placebo arm. Its youngest nonambulatory group gained 5.3 HFMSE points on 2 mg/kg and 7.1 points on 20 mg/kg at 12 months. In the 36-month extension, 35 nonambulatory patients on 20 mg/kg averaged a 4.0-point gain. Without a control group, these larger numbers cannot be compared directly with SAPPHIRE.

4. Can apitegromab protect muscle on tirzepatide?

This is where apitegromab meets the GLP-1 world. The phase 2 EMBRAZE trial randomized 102 adults with overweight or obesity to tirzepatide plus apitegromab 10 mg/kg every 4 weeks, or tirzepatide plus placebo, for 24 weeks. Tirzepatide was titrated to 15 mg weekly, and about four in five participants were women. Body composition was measured by DEXA (dual-energy X-ray absorptiometry) in the 43 and 44 per arm who completed treatment with a week-24 scan.

The difference in lean mass was 1.9 kg in favor of apitegromab (80% CI 1.2–2.7). The authors framed it as keeping 54.9% of the lean mass that would otherwise have been lost. Eight weeks after both drugs stopped, the gap had narrowed to 0.9 kg.

Why this is not yet a muscle-loss solution

• No function benefit. Handheld dynamometer strength and chair sit-to-stand tests did not differ between arms. Cardiometabolic markers did not differ either.
• Lean mass is not only muscle. DEXA lean mass here included the trunk and its organs.
• Loose statistics. The trial reported 80% rather than 95% confidence intervals, and its p-values are nominal.
• Small and short. It was company-sponsored, enrolled about 100 people and ran 24 weeks.

The GLP-1 and muscle loss guide explains why lean-mass loss during treatment is a concern and what else is known about it. No published trial has tested apitegromab with semaglutide, so the EMBRAZE result applies only to tirzepatide.

5. How is apitegromab dosed, and how long does it last?

The Isembyld label sets 10 mg/kg by intravenous infusion every 4 weeks, run over 60–120 minutes at no more than 150 mL per hour. It comes as a 150 mg/3 mL single-dose vial. A 20 mg/kg dose was tested but is not recommended because it added no benefit. Safety and efficacy below age 2 are not established, and no patients aged 65 or older were studied.

Like other antibodies, apitegromab is broken down into peptides and amino acids rather than processed by liver drug-metabolizing enzymes or the kidneys. The label’s population model in SMA patients aged 2–21 gives:

In healthy adults given single doses of 1–30 mg/kg, the phase 1 study found mean half-lives of 24–31 days across dose groups. Blood levels of latent myostatin rose in a sustained, dose-related way. That marker confirms the antibody is binding its target; it does not show muscle growth.

Interactions

The label expects no metabolic drug interactions, and nusinersen and risdiplam did not change apitegromab levels in the population model. The sources reviewed here give no pharmacokinetic interaction data with GLP-1 medicines beyond the EMBRAZE trial itself.

6. What are apitegromab’s side effects?

Fractures

The label’s only warning concerns broken bones. In SAPPHIRE, fractures occurred in 5 of 53 patients (9%) on 10 mg/kg, 3 of 53 (6%) on 20 mg/kg and 1 of 50 (2%) on placebo. Three treated patients broke a femur. In the open-label extension, 22 patients (9%) on 20 mg/kg had fractures, five of them serious femur fractures.

Most patients who broke a bone already had low bone density, earlier fractures or joint contractures, but some fractures had no clear cause such as a fall. The label advises caution in people with low bone density or multiple past fractures. In rats, the label also describes thinning, fissures and fractures of the femoral head and neck at exposures below those in humans on 10 mg/kg. That is a later and fuller assessment than the 2021 company toxicology paper, which had reported no treatment-related findings.

Common reactions

In SAPPHIRE, these occurred in at least 20% of patients on 10 mg/kg and more often than on placebo, with two lower-frequency reactions that had no placebo cases:

Serious pneumonia occurred in three patients on 10 mg/kg and none on placebo. No one in SAPPHIRE stopped treatment because of a side effect. In EMBRAZE, adverse events were reported in 76% on apitegromab and 71% on placebo, with nausea, fatigue and headache more common on the antibody.

Creatine kinase

Creatine kinase (CK or CPK) is an enzyme that leaks from muscle into the blood. It rose in 28% of SAPPHIRE patients on the drug vs 12% on placebo, and three patients exceeded 2.5 times the upper limit of normal. These rises were generally symptomless. In EMBRAZE, one participant stopped the drug after a CK rise that followed a new, vigorous strength-training program.

7. Pregnancy, fertility and hormone questions

No human pregnancy or fertility data exist. The rat findings in the label are notable because no dose was free of effects and the lowest doses gave exposures below human levels:

• Adult rats: lower sperm concentration, disrupted estrous cycles and reduced fertility at all doses.
• Offspring of treated mothers: delayed sexual maturation, altered startle behavior and, at the top dose, impaired male reproductive function.
• Rats dosed when young: reduced fertility in females as adults.

On that basis the label states apitegromab may cause fetal harm and may affect reproductive function. These are animal data, but they are the only data available.

8. Is apitegromab legal, and is it banned in sport?

In the US it is a prescription biologic given by IV infusion. It is an antibody, not a steroid, and it does not appear among the anabolic steroids in 21 CFR 1308.13.

The WADA 2026 Prohibited List names apitegromab in section S4.3 among “myostatin- or precursor-neutralizing antibodies.” S4.3 substances are non-Specified and banned in and out of competition. The same section covers myostatin-binding proteins such as follistatin, decoy activin receptors such as ACE-031, and activin-receptor antibodies such as bimagrumab.

Muscle or strength gains in healthy or trained users have not been the subject of any published trial. The phase 1 study in healthy adults measured safety, drug levels and target binding only.

9. What can actually be measured or tracked?

The trials relied on measures a clinic can repeat. EMBRAZE used DEXA for lean and fat mass, plus strength and sit-to-stand tests. SAPPHIRE used a standardized motor score. A bathroom scale cannot separate lean from fat loss, so it cannot show whether a muscle-preserving drug is doing anything.

Blood tests in the trials included creatine kinase, which rose more often on the drug. The bone and fertility signals come from fracture counts and rat studies, not from a routine lab marker. The sources reviewed here do not set out a specific monitoring schedule beyond the label’s caution in people with fragile bones.

The 4-week infusion interval and 31-day half-life mean exposure builds over months. When logging any change in weight, body composition or strength, record infusion dates alongside GLP-1 doses, training and diet so a clinician can see what changed and when. The peptide half-life tracking guide explains how half-life shapes these curves, and a log cannot by itself show cause and effect.

10. Apitegromab FAQ

• What is apitegromab used for?

  Its only approved use is spinal muscular atrophy (SMA), in patients aged 2 and older who are already receiving an SMN2-targeted drug such as nusinersen or risdiplam. It has also been studied for lean-mass preservation during tirzepatide weight loss, but that use is not approved.

• Is apitegromab FDA approved?

  Yes. The FDA approved it as Isembyld (apitegromab-mstn) on September 11, 2026, after an earlier complete response letter in 2025 that cited only manufacturing-site inspection findings. The EU application was withdrawn in August 2026 and resubmitted in October 2026.

• Can apitegromab be used with semaglutide or tirzepatide?

  The only combination trial, EMBRAZE, paired it with tirzepatide in adults with overweight or obesity. It cut lean-mass loss by 1.9 kg over 24 weeks but did not improve measured strength or function. No published trial has tested it with semaglutide, and no regulator has approved it for use with any GLP-1 medicine.

• What are the side effects of apitegromab?

  The label's main warning is fractures, including serious femur fractures. In the SMA trial, upper respiratory infections, vomiting, cough, headache, gastroenteritis, diarrhea and injection-site reactions were more common on the labeled dose than on placebo. Creatine kinase, a muscle enzyme, also rose more often.

• How long does apitegromab stay in your system?

  The label reports a terminal half-life of about 31 days, from a population model in SMA patients. With dosing every 4 weeks, levels roughly double before reaching steady state at about 16–20 weeks. In EMBRAZE, a smaller lean-mass difference was still seen 8 weeks after treatment stopped.

• Does apitegromab build muscle in healthy people?

  No published trial has tested that. The healthy-adult phase 1 study measured safety, drug levels and target binding, not muscle. Muscle-growth data in healthy animals come from mice.

• Is apitegromab banned in sports?

  Yes. The WADA 2026 Prohibited List names apitegromab under S4.3 as a myostatin- or precursor-neutralizing antibody. S4.3 substances are banned in and out of competition.

• Does apitegromab affect fertility or pregnancy?

  There are no human data. In rats, it reduced sperm concentration, disrupted estrous cycles and lowered fertility at all doses tested, and exposed offspring showed delayed sexual maturation. The label states it may cause fetal harm and may affect reproductive function, based on these animal findings.

11. Sources